HC Wainwright Estimates Zura Bio's Q2 Earnings (NASDAQ:ZURA)

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Analysts at HC Wainwright lifted their Q2 2025 EPS estimates for Zura Bio in a research note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their previous forecast of ($0.21). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio's Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.76) EPS.

Other research analysts have also recently issued research reports about the stock. Guggenheim restated a "buy" rating and set a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Oppenheimer decreased their target price on shares of Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, May 9th. Finally, Chardan Capital decreased their target price on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $14.33.

Zura Bio Stock Performance

Shares of ZURA stock traded down $0.02 during mid-day trading on Wednesday, reaching $1.02. 293,130 shares of the company's stock traded hands, compared to its average volume of 409,446. Zura Bio has a 12 month low of $0.97 and a 12 month high of $5.82. The firm has a 50 day moving average price of $1.25 and a two-hundred day moving average price of $1.88. The firm has a market capitalization of $69.74 million, a PE ratio of -1.46 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02).

Hedge Funds Weigh In On Zura Bio

Several hedge funds have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC grew its holdings in Zura Bio by 34.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company's stock valued at $3,614,000 after purchasing an additional 723,933 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock valued at $6,583,000 after purchasing an additional 2,611,532 shares during the last quarter. Allostery Investments LP grew its stake in Zura Bio by 44.2% in the 1st quarter. Allostery Investments LP now owns 2,329,384 shares of the company's stock worth $3,005,000 after acquiring an additional 714,258 shares in the last quarter. Armistice Capital LLC grew its stake in Zura Bio by 2.4% in the 1st quarter. Armistice Capital LLC now owns 1,536,000 shares of the company's stock worth $1,981,000 after acquiring an additional 36,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Zura Bio by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 955,426 shares of the company's stock worth $2,389,000 after acquiring an additional 42,801 shares in the last quarter. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.